A Phase 1, Open-label, Single-dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 986 Administered Orally to Healthy Volunteers and Subjects With Severely Impaired Renal Function
Phase of Trial: Phase I
Latest Information Update: 14 May 2018
At a glance
- Drugs AMG 986 (Primary)
- Indications Heart failure
- Focus Pharmacokinetics
- Sponsors Amgen
- 31 Aug 2018 Biomarkers information updated
- 04 May 2018 Status changed from active, no longer recruiting to completed.
- 14 Mar 2018 Planned End Date changed from 26 Jun 2018 to 28 Jun 2018.